

# Modelling the role of prophylaxis in malaria prevention

Farai Nyabadza

**Abstract**—Malaria is by far the world's most persistent tropical parasitic disease and is endemic to tropical areas where the climatic and weather conditions allow continuous breeding of the mosquitoes that spread malaria. A mathematical model for the transmission of malaria with prophylaxis prevention is analyzed. The stability analysis of the equilibria is presented with the aim of finding threshold conditions under which malaria clears or persists in the human population. Our results suggest that eradication of mosquitoes and prophylaxis prevention can significantly reduce the malaria burden on the human population.

**Keywords**—prophylaxis prevention, basic reproductive number, stability

## I. INTRODUCTION

Infectious diseases such as malaria, AIDS and cholera continue to claim millions of lives around the world [1]. Global eradication programmes of these infectious diseases have been implemented for many years with some considerable success [2]. Malaria is by far the world's most persistent tropical parasitic disease, with annual estimates of clinical cases ranging from 300 to 500 million, with 86% being in Africa. In Southern Africa, out of an estimated population of 145 million, about 92 million people live in malarious areas [3]. Long term solutions to combating some of these diseases have eluded researchers, because some of these diseases have no cure. Malaria, an infection of the red blood cells caused by *Plasmodium*, is spread by the bite of an infected female anopheles mosquito and is endemic to tropical areas where the climatic and weather conditions allow continuous breeding of the mosquito. For instance, temperature influences anopheline mosquito feeding intervals, population density and the reproductive potential of the *Plasmodium* parasite [4]. There is no vaccine that can provide permanent immunity against malaria. However drugs can be taken in advance before entering a malaria high-risk area to prevent or reduce the possibility of infection. No drug therapy has been found to be completely effective in preventing the infection. Moreover the drug therapy depends on which type of malaria an individual has. Many factors have influenced the resurgence and spread of malaria in recent years. These include mosquito resistance to the usual insecticides, resistance of some parasite strains to the commonly used anti malaria drugs and economic factors that influence the financing of malaria control operations. Most malaria high-risk areas are located in developing countries where (a), the level of education is generally low and (b),

drugs can be purchased without prescriptions. A combination of (a) and (b) generally results in maladministration of the drugs. In particular, Southern Africa is prone to malaria epidemics and the disease is a major cause of mortality with an estimated 200 000 deaths occurring annually. Out of the approximated 139 million people living in Southern Africa, 63% live in malarious areas[5].

A number of studies modeling the effects of vaccination as a disease control mechanism have been carried out by many authors [6], [7], [8]. Kribs-Zaleta and Velasco-Hernandez [8] considered a simple vaccination model in which they found that vaccination may fail to achieve the desired objective of eradicating the epidemic. This conclusion is supported by Blower and Mclean [9] and by Haderler and Castillo [10]. In these studies, the basic reproductive number,  $R_0$ , plays an important role in determining whether a disease can persist or clear in a population. If  $R_0 < 1$  the disease can not invade the population and if  $R_0 > 1$  invasion is always possible and in many cases ending up with the establishment of an endemic disease in steady state.

In a situation where, several strains of the malaria parasite exist, climate changes favor malaria transmission and drug resistance is common, we ask the question, "what is the role played by prophylaxis prevention in malaria control?" We ask a further question, "what is the effect of loss of immunity on the dynamics of the disease?" Particularly, we want to investigate how the use of preventive drugs affects the dynamics of the disease. The model presented in this paper is an SVIRS model with vectorial transmission. Studies of mathematical models of vector transmitted diseases, especially those involving diseases transmitted by mosquitoes, have been considered in [11], [12], [13]. We formulate a host-vector model that treats in a qualitative and quantitative manner the main features of the transmission process. We note that  $R_0$  is a threshold parameter for the local stability of the disease free equilibrium point and we apply the center manifold theory to determine the existence and stability of the endemic equilibria near  $R_0$ .

This paper is arranged as follows; we give the model formulation in the Section II. The model analysis which includes a derivation of the basic reproduction number, stability analysis of the disease free equilibrium point and the endemic equilibrium point is given in Section III. Numerical results are given in Section IV and the discussion and conclusion is Section V.

Farai Nyabadza is with SACEMA (South African Center of Epidemiological Modelling and Analysis), University of Stellenbosch, Stellenbosch 7600, email: nyabadzaf@sun.ac.za

## II. MODEL FORMULATION

The model consists of six ordinary differential equations which specify the rate of change of four categories of individuals in the human population and two categories of the vector population over time. The human population consists of a class susceptible individuals ( $S$ ), a class of individuals under prophylaxis prevention ( $V$ ), a class infected individuals ( $I$ ) and a class of individuals who recover with temporary immunity ( $R$ ), while the vector population consists of a class of susceptible mosquitoes ( $S_v$ ) and a class of infected mosquitoes ( $I_v$ ).

Suppose the human population  $N_H$  (where  $N_H = S + V + I + R$ ) and the vector population  $N_v$  (where  $N_v = S_v + I_v$ ) have constant mortality rates  $\mu$  and  $\nu$  respectively. The mortality rate of the vector population is a sum of the natural and induced (for example by the use of pesticides) mortality rates. A proportion  $\epsilon$  of the population is under chemotherapy (i.e given malaria prevention drugs) while  $(1 - \epsilon)$  are not. Furthermore, therapy only reduces the probability of infection when exposed to pathogens, i.e it offers a degree of protection denoted  $\psi$  with  $(1 - \psi)$  measuring the protection failure of the therapy, so that  $\psi = 0$  means the therapy is completely ineffective in preventing infection, while  $\psi = 1$  means the therapy is very effective i.e no individual under therapy will be infected. We let  $\beta_1, \beta_2$  and  $\beta_3$  be the effective contacts between susceptible individuals and vectors, individuals under prophylaxis prevention and vectors and susceptible vectors and infected individuals respectively. The effective contact rate between the human and vector populations may be defined as the average number of contacts per given time that will lead to the infection of one population if the other population is infectious. It is taken to be the product of the number of bites per vector per host per unit time, the proportion of bites that lead to an infection and the ratio of the vector numbers to the host numbers [14]. Even though the human population under prophylaxis prevention can still be infected and become infections, it will be reasonable to assume that  $\beta_1 > \beta_2$ . The prophylaxis prevention immunity wanes at a rate  $\theta$  and thus the average time of prevention is  $\frac{1}{\theta}$ . We assume a recovery rate  $\gamma$  for infected individuals who loose immunity at a rate  $\sigma$ . The dynamics of the disease is modelled by the following system of differential equations.

$$\begin{aligned}\dot{S}(t) &= \mu(1 - \epsilon)N_H - \mu S(t) - \beta_1 S(t) \frac{I_v(t)}{N_v} + \theta V(t) + \sigma R, \\ \dot{V}(t) &= \mu \epsilon N_H - (1 - \psi)\beta_2 V(t) \frac{I_v(t)}{N_v} - (\mu + \theta)V(t) \\ \dot{I}(t) &= \beta_1 S(t) \frac{I_v(t)}{N_v} + (1 - \psi)\beta_2 V(t) \frac{I_v(t)}{N_v} - (\gamma + \mu)I(t), \\ \dot{R}(t) &= \gamma I(t) - (\mu + \sigma)R(t) \\ \dot{S}_v(t) &= \nu N_v - \nu S_v(t) - \beta_3 S_v(t) \frac{I(t)}{N_H} \\ \dot{I}_v(t) &= \beta_3 S_v(t) \frac{I(t)}{N_H} - \nu I_v(t).\end{aligned}\quad (1)$$

All parameters in the model are positive. Introducing the following fractions  $s = \frac{S(t)}{N_H}$ ,  $v = \frac{V(t)}{N_H}$ ,  $i = \frac{I(t)}{N_H}$ ,  $r = \frac{R(t)}{N_H}$ ,  $s_v = \frac{S_v(t)}{N_v}$  and  $i_v = \frac{I_v(t)}{N_v}$  and using the relations  $r = 1 - v - i - s$  and  $s_v = 1 - i_v$  system (1) reduces to

$$\dot{s} = \pi - (\mu + \sigma)s - \beta_1 s i_v + (\theta - \sigma)v - \sigma i, \quad (2)$$

$$\dot{v} = \mu \epsilon - (1 - \psi)\beta_2 v i_v - (\mu + \theta)v, \quad (3)$$

$$\dot{i} = \beta_1 s i_v + (1 - \psi)\beta_2 v i_v - (\gamma + \mu)i, \quad (4)$$

$$\dot{i}_v = \beta_3 i(1 - i_v) - \nu i_v. \quad (5)$$

where  $\pi = \mu(1 - \epsilon) + \sigma$ , in the region

$$\Omega = \{(s, v, i, i_v) | 0 \leq s + v + i \leq 1, 0 \leq i_v \leq 1\}.$$

The vector field of system (2) - (5) on the boundary of  $\Omega$  does not point to the exterior of  $\Omega$ , the solution of the system remains in  $\Omega$  for all  $t > 0$  and thus the problem is well posed and biologically meaningful. The disease free equilibrium, **DFE**, point for system (2) - (5) is given by  $E_0 = (1 - \phi, \phi, 0, 0)$  and is determined in Subsection III-B.

## III. MODEL ANALYSIS

### A. The reproduction number

We arrange the equations of system (2) - (5) beginning with the infectives and use the method given in [15] to determine the basic reproductive number. The method is a direct application of lemma 1 in [15]. The decomposition of the model into components  $\mathcal{P}$  and  $\mathcal{Q}$  leads to a system of the form  $\dot{\mathcal{X}} = \mathcal{P} - \mathcal{Q}$  where

$$\mathcal{P} = \begin{pmatrix} \beta_1 s i_v + (1 - \psi)\beta_2 v i_v \\ \beta_3 i(1 - i_v) \\ 0 \\ 0 \end{pmatrix}, \quad \mathcal{Q} = \begin{pmatrix} (\gamma + \mu)i \\ \nu i_v \\ \beta_1 s i_v + (\mu + \sigma)s + \sigma i - (\theta - \sigma)v - \pi \\ (1 - \psi)\beta_2 v i_v + (\mu + \theta)v - \mu \epsilon \end{pmatrix}$$

and  $\mathcal{X} = (i, i_v, s, v)^T$ . Since the infected compartments are  $i$  and  $i_v$ , at the disease free equilibrium point we define

$$P = \left[ \frac{\partial \mathcal{P}_i}{\partial x_j} \right] \text{ and } Q = \left[ \frac{\partial \mathcal{Q}_i}{\partial x_j} \right] \text{ for } 1 \leq i, j \leq 2$$

giving

$$P = \begin{pmatrix} 0 & \beta_1(1 - \phi) + (1 - \psi)\beta_2\phi \\ \beta_3 & 0 \end{pmatrix}, \text{ and}$$

$$Q = \begin{pmatrix} (\gamma + \mu) & 0 \\ 0 & \nu \end{pmatrix} \text{ where } \phi = \frac{\mu \epsilon}{\mu + \theta}.$$

From this expression for  $\phi$ , we note that  $\phi = \frac{\mu \epsilon}{\mu + \theta} = \frac{\theta}{\mu + \theta} \frac{\mu \epsilon}{\theta}$ .  $\frac{\mu \epsilon}{\theta}$  represents the number of individuals successfully protected by chemoprevention with probability  $\frac{\theta}{\mu + \theta}$ .

Note that  $P$  is nonnegative,  $Q$  is a nonsingular  $M$ -matrix, its inverse,  $Q^{-1}$  is nonnegative and  $PQ^{-1}$  is nonnegative. According to [16],  $PQ^{-1}$  is the next generation matrix and  $R^0$  is the spectral radius of  $PQ^{-1}$ . In this case, if

$$\mathcal{A} = PQ^{-1} = \begin{pmatrix} 0 & \frac{1}{\nu}(\beta_1(1 - \phi) + (1 - \psi)\beta_2\phi) \\ \frac{\beta_3}{\mu + \gamma} & 0 \end{pmatrix}$$

then, the eigenvalues of  $\mathcal{A}$  are given by

$$\lambda_{1,2} = \pm \sqrt{\frac{\beta_3(\beta_1(1 - \phi) + (1 - \psi)\beta_2\phi)}{\nu(\gamma + \mu)}}.$$

Hence the effective reproductive number is given by

$$R = \sqrt{\frac{\beta_3(\beta_1(1-\phi) + (1-\psi)\beta_2\phi)}{\nu(\gamma + \mu)}} = \sqrt{R_v \cdot R_h},$$

where  $R_v = \frac{\beta_3}{\nu}$ , and

$$R_h = (1-\phi)R_1 + \phi(1-\psi)R_2,$$

with  $R_1 = \frac{\beta_1}{\mu+\gamma}$  and  $R_2 = \frac{\beta_2}{\mu+\gamma}$ .

The geometric mean of the product  $R_v R_h$ , defines the mean number of secondary cases generated by a single case of an infection by an infectious mosquito or human being during their infectious period, in a susceptible population in which prophylaxis prevention is in use. Close to the **DFE** point, each infected vector produces  $R_h$  newly infected individuals over its expected infectious period and each infected individuals produces  $R_v$  newly infected mosquitoes during the period of infectiousness. The reproduction number with a square root is due to the two generations required for an infection to be reproduced [15]. The two terms of  $R_h$  measure the influence of individuals not under prophylaxis prevention and those under prophylaxis prevention respectively.

By setting  $R = 1$ , the critical prophylaxis prevention coverage  $\epsilon^*$  that would be required to contain malaria can be calculated. The case  $\beta_1 = \beta_2$  gives

$$R_v R_h = R_0 (1 - \epsilon\beta)$$

where  $\beta = \frac{\mu\psi}{\mu+\theta}$ ,  $R_0 = R_v R_1$ .

Here  $R_0 = R_v R_1$  is the basic reproduction number, i.e the number of new infection cases that result from a single case of an infection in a population that is wholly susceptible when no intervention is in place. We note that  $\beta$  is the impact or efficacy of the vaccine and for the human population, the critical prophylaxis prevention coverage,  $\epsilon^*$  is given by

$$\epsilon^* = \frac{1}{\beta} \left( 1 - \frac{1}{R_0} \right). \quad (6)$$

For the case where  $\beta_1 \neq \beta_2$ , the critical prophylaxis prevention coverage is given by

$$\epsilon_* = \frac{\mu + \theta}{\mu} \left( \frac{1 - R_0}{(1-\psi)R_m - R_0} \right) \quad (7)$$

where  $R_m = R_v R_2$ . The expression (7) collapses to (6) for  $\beta_1 = \beta_2$ .

To investigate the impact of taking prophylactic vaccines on the permanence of the malaria infection, we consider a limiting case  $\psi \rightarrow 1$ . We note that

$$\lim_{\psi \rightarrow 1} R_h R_v = (1 - \phi)R_0.$$

We also note that,

$$\frac{\partial R_h}{\partial \psi} < 0.$$

This means that  $R_h$  is a decreasing function of  $\psi$  and consequently as  $\psi$  increases,  $R$  decrease. This means that as the protection against malaria improves, the number of secondary

infections decreases. In developing countries, governments and non-governmental organisations have been distributing chemically treated mosquito nets in order to increase the level of protection.

In the absence of intervention i.e when  $\phi = 0$ , we have  $R_h R_v = R_0$ . A comparison of  $R_h R_v$  and  $R_0$  results in the following lemma;

*Lemma 1:*  $R_0 > R_v R_h$  whenever  $\psi^* > \left(1 - \frac{\beta_2}{\beta_1}\right)$ .

We omit the proof of the proposition, which can easily be established.

**Remark:**  $\psi^*$  is thus a threshold parameter, because for intervention to have an impact on the control of malaria,  $\psi$  must exceed the ratio  $\frac{\beta_1 - \beta_2}{\beta_1}$ . This ratio is important to public health intervention programs. It sets the minimum value for the degree of protection that a therapy should achieve for an intervention to be effective. We shall now assume that this condition is satisfied in our analysis of the equilibrium point.

### B. Disease free equilibrium point

From equations (2), (3) and (5), the equilibrium points must satisfy the following relations in terms of  $i$ :

$$i_v = \frac{R_v i}{1 + R_v i} \quad (8)$$

$$v = \phi \frac{1 + R_v i}{1 + \mathcal{U} R_v i} \quad (9)$$

$$s = \frac{(\alpha_1 + \alpha_2 i + \alpha_3 i^2)(1 + R_v i)}{(\sigma + \mu)(1 + \mathcal{U} R_v i)(1 + \mathcal{T} R_v i)} \quad (10)$$

where  $\mathcal{U} = 1 + \frac{(1-\psi)\beta_2}{\mu+\theta}$ ,  $\mathcal{T} = 1 + \frac{\beta_1}{\mu+\sigma}$  and  $\alpha_1 = (\mu + \sigma)(1 - \phi)$ ,

$\alpha_2 = (\mu + \sigma)(1 - \phi)R_v + \frac{\pi(1-\psi)\beta_2}{(\mu+\theta)}R_v - \sigma$  and  $\alpha_3 = -\sigma\mathcal{U}R_v$ .

Substituting equations (8), (9) and (10) into (4) and equating to zero, we get  $i = 0$  and the quadratic equation

$$F(i) = Ai^2 + Bi + C = 0, \quad (11)$$

where

$$A = -R_v^2 \mathcal{U} [\beta_1(\mu + \gamma + \sigma) + (\mu + \gamma)(\mu + \sigma)],$$

$$B = R_v \left[ C + \mathcal{U}A + \frac{(\mu + \gamma)(\mu + \sigma)}{\mu + \theta} (1 - \psi)\beta_2 (R_0 - 1) \right],$$

$$C = (\mu + \gamma)(\mu + \sigma)(R - 1).$$

Taking  $i = 0$  and substituting into (8), (9) and (10) gives the disease free equilibrium point

$$E_0 = (1 - \phi, \phi, 0, 0).$$

The case  $i \neq 0$  is considered in the next section .

*Theorem 1:* If  $R < 1$ , then the **DFE** point,  $E_0$  is locally asymptotically stable in  $\Omega$ , and unstable for  $R > 1$ .

*Proof:* The Jacobian of system (2) - (5) at  $E_0$  has two eigenvalues  $l_1 = -(\mu + \sigma)$ ,  $l_2 = -(\mu + \theta)$  and the other two have negative real parts if and only if  $R < 1$ . Thus the **DFE** point is locally asymptotically stable if  $R < 1$  and unstable if  $R > 1$ . ■

### C. The endemic equilibria

A solution  $i$ , of (11) corresponds to an endemic equilibrium solution. From (11) it is easy to observe that  $A < 0$ ,

$$C \begin{cases} < 0 & \text{if } R < 1 \\ > 0 & \text{if } R > 1 \end{cases} \quad \text{and } B < 0 \text{ if } R < 1, R_0 < 1.$$

Equation (11) has multiple solutions that depend on the parameter values chosen. So, the model has multiple equilibria of coexistence. We draw the following results on the existence of multiple endemic equilibria:

**Theorem 2:** (a) System (2) - (5) has only one positive equilibrium point if  $R > 1$ .

(b) If  $R < 1$  and  $B > 0$  then system (2) - (5) has two positive equilibrium solutions.

(c) If  $R < 1$  and  $R_0 < 1$ , then no positive equilibria exist for system (2) - (5).

Result (b) of the above theorem, suggests the coexistence of the endemic equilibrium point and the disease free equilibrium point, a phenomena known as backward bifurcation.

For  $\psi = 1$ , we note that  $\mathcal{U} = 1$ ,  $\alpha_2 = (\mu + \sigma)(1 - \phi)R_v - \sigma$ ,  $\alpha_3 = -\sigma R_v$  and  $R_h = (1 - \phi)R_1 = \mathfrak{R}$ . The system has a unique stable endemic equilibrium whenever  $\mathfrak{R} > 1$  given by,  $E_1(s^*, v^*, i^*, I_v^*)$ , where

$$\begin{aligned} v^* &= \phi \\ i^* &= \eta(\mathfrak{R} - 1), \\ \text{for } \eta &= \frac{(\mu + \gamma)(\mu + \sigma)}{R_v[(\mu + \gamma)(\mu + \sigma) + \beta_1(\mu + \sigma + \gamma)]}, \\ i_v^* &= \frac{R_v i^*}{1 + R_v i^*} \\ s^* &= \frac{(\mu + \sigma)(1 - \phi) - \sigma i^*}{\mu + \sigma + \beta_1 i_v^*}. \end{aligned}$$

### IV. NUMERICAL RESULTS

In the previous section, the qualitative analysis of the model is presented. The conditions for local and global stability are presented. We now consider numerical results for the model using Matlab and Mathematica.

Malaria is a major cause of mortality in Southern Africa and the burden is greatest among children under the age of five years and pregnant women [3]. Between 10 million and 37 million confirmed cases of malaria occur annually. It is estimated that up to 200 000 malaria deaths occur annually in Southern Africa, with the following estimated percentage distributions in Table I [5].

Country	% distribution	Country	% distribution
Angola	16.4	South Africa	0.2
Botswana	0.1	Swaziland	0.1
Malawi	14.7	Tanzania	32.1
Mozambique	22.3	Zambia	9.3
Namibia	0.1	Zimbabwe	4.6

TABLE I

ESTIMATED DISTRIBUTION OF MALARIA DEATHS IN SOUTHERN AFRICA.

is taken to be 2 – 3 weeks giving  $0.04 \leq \nu \leq 0.06$  years [18]. These values represent the natural death rate of the mosquitoes. It is however apparent that in reality  $\nu$  is higher than these values and difficult to measure. For the purpose of these simulations we shall consider  $\nu \geq 0.06$ . The incidence of confirmed malaria cases is between 73 and 266 per 1000 individuals per annum. The death rate due to malaria can be calculated to be 0.0014 [5]. The period of prophylaxis prevention is estimated to be 15-37 days and the duration of protection of temporary immunity is estimated to be 28 days [19]. It is important to note that many of the model parameters are difficult to estimate but indirect parameter estimates can be obtained from the estimates of the quantities that are measured directly. For example, the rate of recovery of infected individuals can be obtained from the confirmed malaria cases and the estimates of deaths. The rate of recovery per annum  $\gamma$  is thus calculated to be approximately 0.98. The effective contact rate of humans to vectors is 0.375 and from vectors to humans is 0.75 [20]. Some authors assume a transmission rate from humans to vectors of about 0.4167 [14]. The parameter values for the model are listed in Table II.

Parameter	Approx. values/year	Parameter	Approx. values/year
$\epsilon$	$0 < \epsilon < 1$	$\mu$	0.0264
$\psi$	$0 \leq \psi \leq 1$	$\gamma$	0.98
$\beta_1$	$\beta_1 > 0.375$	$\theta$	$0.04 \leq \theta \leq 0.1$
$\beta_2$	$\beta_2 < 0.3$	$\nu$	$\nu \geq 0.06$
$\beta_3$	0.75	$\sigma$	0.08

TABLE II  
PARAMETER VALUES

The following initial conditions are assumed for the proportions;  $s(0) = 0.6$ ,  $v(0) = 0.2$ ,  $i(0) = 0.1$  and  $z(0) = 0.1$  in our simulations. Simulations were run for different sets of initial conditions and the qualitative form of the solutions were similar.

We begin by looking at the prevalence curve for the human population for the parameter values given in the caption of Figure 1. In this case the vector population plays an important role in the overall disease transmission as seen from the value of the reproduction number  $R_v$ . A decrease in the contribution of the vector to the overall transmission of malaria leads to a decrease in the prevalence of malaria. The implications of a declining prevalence are related to the eradication of malaria. The waning duration of a prophylaxis is of great importance in disease prevention. If it is short, then the desired results are likely not to be achieved. If it is long then individuals are assured of protection for longer periods. Below is a graph showing the corresponding long term evolution of the prevalence curves for changing values of  $\theta$ . We note that increasing the values of  $\theta$  leads to an increase in the reproduction number. For the given values of  $\theta$  in the table, increasing  $\theta$  implies reduced duration of protection.

In Southern Africa the human life span is taken to be 14 600 days (40 years) so that  $\mu = 0.025$  [17]. The vectors life span




Fig. 1. The evolution of prevalence for the human population over time for the following parameter values,  $\pi = 0.2$ ,  $\mu = 0.0264$ ,  $\sigma = 0.08$ ,  $\theta = 0.06$ ,  $\epsilon = 0.2$ ,  $\psi = 0.5$ ,  $\gamma = 0.98$ ,  $\beta_1 = 0.46$ ,  $\beta_2 = 0.2$ ,  $\beta_3 = 0.75$  and  $R_h = 0.4352$ .




Fig. 2. The evolution of prevalence for the human population over time for the following parameter values,  $\pi = 0.2$ ,  $\mu = 0.0264$ ,  $\sigma = 0.08$ ,  $\nu = 0.4$ ,  $\epsilon = 0.2$ ,  $\psi = 0.5$ ,  $\gamma = 0.98$ ,  $\beta_1 = 0.46$ ,  $\beta_2 = 0.2$ ,  $\beta_3 = 0.75$  and  $R_v = 1.8750$ .

We noted that  $\frac{\partial R_h}{\partial \psi} < 0$ . Consequently, as  $\psi$  increases  $R$  decreases. The result is supported numerically by the graph below.

## V. CONCLUSION

Presented in this paper is the influence of prophylaxis prevention in the spread of malaria. prophylaxis prevention is meant to reduce susceptibility to infection and like vaccines, it is characterized by two important parameters given in the model: the the degree of protection  $\psi$  and the waning period  $\theta$ . The model presented in this paper is perhaps the simplest caricature possible of a prophylaxis prevention




Fig. 3. The relationship between  $\psi$  and the reproduction number  $R$  for the following parameter values,  $\pi = 0.2$ ,  $\mu = 0.0264$ ,  $\sigma = 0.08$ ,  $\theta = 0.06$ ,  $\epsilon = 0.2$ ,  $\gamma = 0.98$ ,  $\beta_1 = 0.46$ ,  $\beta_2 = 0.2$ ,  $\beta_3 = 0.75$ ,  $\nu = 0.35$

program applied to a general population. The results show that prophylaxis are capable of reducing malaria epidemics if issues related to drug/pesticides resistance are seriously taken into consideration. Models that look into the issues of drug resistance were considered in [21].

The model analysis included the determination of equilibrium points and carrying out their stability analysis in terms of the preventive therapy reproduction number  $R$ . We note that  $R$  is a product of two terms  $R_v$  and  $R_h$ . From the expression

$$R = (1 - \phi)R_0 + (1 - \psi)\phi R_m,$$

$\phi$  is the probability that an individual is successfully protected by chemoprevention,  $R_0$  is the mean number of secondary cases of malaria produced by a single case of infection in a population that is wholly susceptible with no chemoprevention intervention in place.  $R_m$  is the mean number of secondary cases of malaria that are produced by an individual who is successfully protected by prophylaxis prevention and becomes infected during his or her life time.

This work can provide insights into several aspects of the malaria control. It is important to acknowledge that the dynamics of malaria transmission are not simple. Malaria transmission in Southern Africa has been affected by funding and service delivery, political instability (the cases of Mozambique, Angola and the Democratic Republic of Congo), poverty, drug and insecticide resistance. The evolution of these biological and social systems is complex, making it impossible for mathematical models to provide accurate predictions of the disease dynamics. They can however be used to forecast, but only in fairly gross terms. Modelling should be an integral part of any disease control program and the model system should be easy to use and can be adapted to new results and changes in control policies [22].

Vector control plays a central role in the control of malaria. Problems specific to vector control are insecticide resistance, species identification and control strategy choices. Overall,

mathematical models can assist in determining control strategies with large impacts on outcomes and can provide comprehensive evaluation of model assumptions that influence decisions.

#### ACKNOWLEDGMENT

The author would like to thank SACEMA for their support in the production of this manuscript.

#### REFERENCES

- [1] S. Busenberg and K. Cooke, *Vertically transmitted diseases - models and dynamics*, Springer-Verlag, 1993.
- [2] N. T. J. Bailey, *The Biomathematics of Malaria*, A Charles Griffin Book, 1981.
- [3] B. Chilundo, J. Sundby and M. Aanestad, 2004. *Analyzing the quality of routine malaria data in Mozambique*, Malaria Journal **3**(3), 1-11.
- [4] J. Small, S. J. Goetz and S. I. Hay, 2003. *Climatic suitability for malaria transmission in Africa, 1911-1995*, Applied Biological Science, **100**(26), 15341-15345.
- [5] The Burden of Malaria in Southern Africa, Retrieved from [http://www.malaria.org.zw/malaria\\_burden.html](http://www.malaria.org.zw/malaria_burden.html) on 10 July 2006.
- [6] K. Dietz K., 1988. *Mathematical models for transmission and control of malaria*. In Malaria - Principles and Practice of Malariology **2** (Churchill Livingstone), W. H. Wernsdorfer and Sir I. McGregor.
- [7] A. N. Hill and I. M. Longini Jr., 2003. *The critical vaccination fraction for heterogeneous epidemic models*, Mathematical Biosciences, **181**, 85-106.
- [8] C. M. Kribs-Zaleta and J. X. Velasco-Hernandez, 2000. *A simple vaccination model with multiple endemic states*, Mathematical Biosciences, **164**, 183-201.
- [9] S. Blower, K. Koelle and J. Mills, 2002. *Health policy modeling: epidemic control, HIV vaccines and risky behavior*. Quantitative Evaluation of HIV Prevention Programs (Yale University Press, 2002), 260-289, Kaplan and Brookmeyer.
- [10] K. P. Haderl and C. Castillo-Chavez, 1995. *A Core Group Model for Disease Transmission*, Mathematical Biosciences, **128**, 41-55.
- [11] L. Esteva and C. Vargas, 1999. *A model for dengue disease with variable human population*, Journal of Mathematical Biology, **38**, 220-240.
- [12] L. Esteva and M. Matias, 2001. *A model for vector transmitted diseases with saturation incidence*, Journal of Biological Systems, **9**, 235-245.
- [13] L. Esteva and C. Vargas, 2003. *Coexistence of different serotypes of dengue virus*, Journal of Mathematical Biology, **46**, 31-47.
- [14] G. A. Ngwa and W. S. Shu, 2000. *A mathematical model for endemic malaria with variable human and mosquito populations*, Mathematical and Computer Modelling, **32**, 747-763.
- [15] P. van den Driessche and J. Watmough, 2002. *Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission*, Mathematical Biosciences, **180**, 29-48.
- [16] O. Diekmann, J. Heesterbeek and J. Metz, 1990. *On the definition and the computation of the basic reproductive ratio  $r_0$  in models of infectious diseases in heterogeneous populations*, Journal of Mathematical Biology, **28**, 356-382.
- [17] Press Release WHO, 4 June 2000, *WHO Issues New Healthy Life Expectancy Rankings Japan Number One in New Healthy Life System*, World Health Organisation.
- [18] Anopheles Mosquito, retrieved from <http://www.anopheles.com>, on 10 July 2006.
- [19] W. O'Meara, D. L. Smith and F. E. McKenzie, 2006. *Potential impact of intermittent preventive treatment on spread of drug-resistant malaria*, PLoS Medicine, **3**(5), 63-642.
- [20] A. Derouich and A. Boutayeb, 2006. *Dengue fever; mathematical modelling and computer simulation*, Applied Mathematics and Computation, **177**, 528-544.
- [21] J. C. Koella and R. Antia, 2003. *Epidemiological models for the spread of anti-malaria resistance*, Malaria Journal, **2**(3), 1-11.
- [22] F. E. McKenzie and E. M. Samba, 2004. *The role of mathematical modelling in evidence-based malaria control*, American Journal of Tropical Medicine and Hygiene, **71**(2) 94-96.